2022
DOI: 10.1093/neuonc/noac209.822
|View full text |Cite
|
Sign up to set email alerts
|

Exth-23. Bicistronic Car-T Cells Targeting Egfr and Il13rα2 Mitigate Antigenic Heterogeneity in Glioma

Abstract: Chimeric antigen receptor (CAR)-T cells have had a significant effect in hematological diseases, with a recent study confirming that the cells can last for ten years in vivo. Unfortunately, to date, CAR-T cells have had little effect in solid tumors. One cause of the treatment difficulty is antigenic heterogeneity. Our experience with CAR-T cells in glioblastoma suggests that addressing antigenic heterogeneity may improve the clinical efficacy. Targeting the epidermal growth factor receptor (EGFR) and interleu… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles